Cohance Lifescience Receives USFDA Form 483 With Four Observations at Telangana Formulation Plant
核心洞察
Cohance Lifescience (搜索) received a USFDA (搜索) Form 483 containing four observations following an inspection of its finished dosage form (FDF) plant in Shamshabad, Telangana.
The inspection ran from August 27 to September 4, 2026, and the company has initiated corrective and preventive actions (CAPA) with a response due within the stipulated timeline.
The company did not disclose the nature of the observations but reaffirmed its commitment to quality and regulatory compliance.
Cohance Lifescience (搜索) has received a US Food and Drug Administration (USFDA (搜索)) Form 483 containing four observations following an inspection of its finished dosage form (FDF) manufacturing plant located in Shamshabad, Telangana. The company announced the development in an exchange filing issued on Saturday, September 5, stating that the inspection concluded with the issuance of a Form FDA 483 containing four observations.
The USFDA (搜索) conducted its inspection at the formulation facility from August 27 to September 4, 2026. According to the US-based drug regulator, a Form 483 observation is a documented finding issued by FDA inspectors following an on-site inspection of a facility, enumerating conditions or actions that could potentially violate federal regulations concerning safety and quality.
Cohance said it has initiated appropriate corrective and preventive actions (CAPA) and will submit its response to the US regulator within the stipulated timeline. The company did not elaborate on the specific nature of the observations, stating only that it "remains committed to quality and regulatory compliance."
A USFDA (搜索) Form 483 is issued by agency inspectors when they identify conditions or practices during an inspection that may potentially violate applicable regulatory requirements. The issuance of the form does not by itself represent a final determination of non-compliance, with the company generally given an opportunity to respond and address the observations.
ADC Expansion Strategy
The regulatory development comes at a time when Cohance is expanding its presence in advanced therapies, particularly antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer treatments. The company recently announced plans to invest a combined $18 million in New Jersey-based NJ Bio (搜索) and Aruka Bio (搜索) as part of its strategy to strengthen its position in the ADC segment.
Of the total investment, Cohance plans to invest $13 million in NJ Bio (搜索), increasing its ownership, and a further $5 million in Aruka Bio (搜索). Following completion of the transaction and an initial equity allocation to Jain, Cohance is expected to directly control 65% of Aruka Bio, while NJ Bio will hold a 25% stake and Jain will hold the remaining 10%.
Stock Performance
Cohance Lifescience (搜索) shares ended Friday's trading session more than 1% higher. Despite the day's gains, the stock has faced significant pressure over the past year, declining more than 50% in the period. The shares were priced at Rs 456.55, remaining 56.20% below their 52-week high of Rs 1,038.90. The stock has also closed lower in four of the last 10 trading sessions.